The present invention encompasses a modified human urokinase plasminogen activator ("huPA") gene, which was inserted in the adenoviral vector (pAd-.DELTA.huPA), which is not secreted and does not provoke hypercoagulation or spontaneous internal bleeding. It has been discovered that huPa induced a dramatic fibrosis reduction (85%) on day 10 of vector administration, compared to control cirrhotic rats and 55% hepatocyte proliferation increase. Liver function tests (ALT, AST, alkaline phosphatase and bilirubin) dropped to nearly normal levels and hepatocyte proliferation was observed. The invention also encompasses gene therapy with modified huPA to treat disorders in patients. In a particular embodiment, the invention encompasses a treatment for patients with liver cirrhosis.

TGT Laboratories, S.A. De C.V.

Recombinant viral and non-viral vectors containing the human urokinase plasminogen activator gene and its utilization in the treatment of various types of hepatic, renal, pulmonary, pancreatic and cardiac fibrosis and hypertrophic scars

The invention relates to an in vitro process for diagnosing cystic fibrosis, which brings into play conditions, particularly temperatures at which some of the hydrolases released by the cells from the individual under study, particularly .alpha.-mannosidase and acid phosphatase, are subject to greater inactivation kinetics, when the cells originated from individuals affected by the disease or capable of transmitting it, than when said cells were from healthy people. The process thus consists of maintaining such cells, either in natural biological media or in culture media at a temperature within said intervals for a time long enough to appreciate the degree or kinetics of inactivation which can then be correlated to the fact that the individual is either healthy or affected by the disease or liable of transmitting it.

fibrosis/phosphatase

Recombinant viral and non-viral vectors containing the human urokinase plasminogen activator gene and its utilization in the treatment of various types of hepatic, renal, pulmonary, pancreatic and cardiac fibrosis and hypertrophic scars

Process of in vitro diagnosis of cystic fibrosis

Bilim tarafından desteklenen en eksiksiz şifalı otlar veritabanı